Boston Scientific is counting on its interventional cardiology and peripheral interventions businesses to lead it back to revenue growth in 2021.
Boston Scientific Is Counting On COVID-19 Vaccine To Rebound In 2021
The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.
